UK small-cap RNS · 13 Jul 2026
Every announcement of UK small & mid caps under £2bn. The ones that started or moved a situation are marked – a click opens it.
Key = all announcements except routine filings (voting rights, buybacks, holdings, director forms), plus the ones that are part of a situation. Not investment advice.
| Time | Company | Mcap ↕ | Type | Announcement | |
|---|---|---|---|---|---|
| 14:35 | B.P. Marsh & Partners BPM | £245m | Insider conviction | Director/PDMR Shareholding | |
| 11:51 | Galantas Gold Corp. GAL | £172m | Project milestones | Agreement to Acquire Crushing Plant for Andacollo
§ Major Milestone Significantly Advances Project Execution and Reduces Restart Capital |
|
| 08:37 | CloudCoco Group CLCO | £1.7m | Insider conviction | Director/PDMR Shareholding | |
| 07:51 | Physiomics PYC | £2.2m | Insider conviction | Director/PDMR Shareholding | |
| 07:00 | Gelion GELN | £42m | New CEO / reset | Issue of Q2 Newsletter
From expanding relationships with global industry leaders and advancing multiple commercialisation pathways, to positioning the business for accelerated growth under new CEO Matt Wood, Gelion continues to build momentum across its key markets of Japan, the … |
|
| 07:00 | Acuity RM Group ACRM | £5.2m | Turnaround plan with targets | First sale of the new STREAM® Cloud platform
Acuity RM Group plc (AIM: ACRM), the software group specialising in the cybersecurity sector of the Governance, Risk and Compliance ("GRC") market, announces the first sale of its new STREAM® Cloud multi-tenant platform, to a leading provider of funeral … |
|
| 07:00 | PureTech Health PRTC | £268m | Disposal of a part (break-up) | Celea Doses 1st Patient in Phase 3 IPF Trial
PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) |
|
| 07:00 | Bango BGO | £60m | Insider conviction | Director/PDMR Shareholding | |
| 07:00 | Zenith Energy LTD.Com Shs ZEN | £29m | Disposal of a part (break-up) | Rome acquisition brings solar pipeline to 193 MWp
With construction now underway on the Company's first solar plants in Puglia, Zenith continues to build its Italian pipeline towards the 200 MWp target, acquiring a second site in Rome at an attractive entry cost of EUR 70,000 per hectare. |
|
| 07:00 | Genedrive GDR | £18m | Project milestones | Trading Update
- Strong commercial progress and poised for continued growth in the next 12 months |
|
| 07:00 | Sabien Technology Group SNT | £0.9m | Disposal of a part (break-up) | Year End Trading Update
During FY2026 the Company focused on transforming Sabien into a higher-margin technology business centred on its M2G Cloud Connect platform, whilst strengthening its balance sheet and evaluating strategic opportunities to accelerate long-term shareholder … |
|
| 07:00 | Concurrent Technologies CNC | £250m | Segment turn | Trading Update
Concurrent Technologies Plc (AIM: CNC), a designer and manufacturer of leading-edge computer products, systems and mission critical solutions used in high-performance markets by some of the world's major OEMs, provides an update on trading for the six months … |
|
| 07:00 | Me Group International MEGP | £417m | Upgrade / downgrade cycle | 2026 Interim Results
Interim Results for the six months ended 30 April 2026 |
|
| 07:00 | Brave Bison Group BBSN | £85m | Takeover target | Possible Offer for System1 Group Plc
("Brave Bison" or the "Company", together with its subsidiaries "the Group") |